Posts

Vemurafenib FDA approved for treatment of Erdheim-Chester Disease with BRAF V600 mutation

On 6 November 2017, the FDA granted regular approval to vemurafenib (Zelboraf®, Roche) for the treatment of patients with Erdheim-Chester Disease (ECD) harbouring a BRAF V600 mutation.